Actualités sur Virus

Schweizerischer Nationalfonds / Fonds national suisse

Wastewater provides new insight into Covid-19 dynamics

Bern (ots) - An interdisciplinary team funded by the Swiss National Science Foundation shows that the R number of coronavirus can be estimated quickly and cost-effectively from wastewater. Since the start of the coronavirus (Sars-Cov-2) pandemic, many public health measures have been decided based on its dynamic of spread, more precisely, on the reproductive number of the virus, known as the R number. This value indicates ...

Schweizerischer Nationalfonds / Fonds national suisse

Innovative research into new vaccines

Bern (ots) - Projects taking part in the National Research Programme "Covid-19" (NRP 78) of the Swiss National Science Foundation (SNSF) are pursuing highly promising approaches in a drive to develop new vaccines. Three research groups have adopted interesting approaches to the highly topical issue of vaccines. The team led by Steve Pascolo is investigating ways of improving functionality and stability of mRNA vaccines, ...

News Direct

Microban® International Announces a New Range of Antiviral Technologies

Shycocan

TNO research shows effectiveness of corona cannon

Rijswijk, Netherlands (ots/PRNewswire) - Addition due to incomplete information in the press release as sent on 4 June 2021 Analyses carried out by TNO in a BSL-3 laboratory cabinet showed that the corona gun had achieved a 94.9% reduction in the Covid -19 virus after 15 minutes. In the laboratory set-up, the (live) virus was located on stainless steel plates at 85 cm from the device. Earlier, the Dutch scientific ...

Debiopharm International SA

DEBIOPHARM COLLABORATES WITH INNOCENTIVE FOR THE LAUNCH OF A GLOBAL CHALLENGE TO DEVELOP A SINGLE-DOSE mRNA COVID-19 VACCINE

Lausanne, Switzerland (ots) - - Currently approved COVID-19 vaccines based on messenger RNA (mRNA) technology require two injections, given several weeks apart, for optimal protection against the virus - Debiopharm has launched a vaccine innovation challenge to a pool of international “problem Solvers” within ...

Intravacc

Intravacc announces positive preclinical data for its SARS-CoV-2 nose spray vaccine

Bilthoven, Netherlands (ots/PRNewswire) - - Intranasal administration of OMV-Spike protected against challenge with SARS-CoV-2 - Intranasal vaccine administration has significant advantages over injectables - OMV technology is a powerful vaccine platform for future pandemics Intravacc, a global leader in translational research and development of viral and bacterial ...

DG-Nika AG

2

First pocket inhaler for Covid-19 and other viral mutations

Swiss Rockets AG

Swiss Rockets AG announces the founding of ROCKETVAX for the development of a next-generation SARS-CoV-2 vaccine

Magnostics Ltd

Magnostics is Co-Developing and Launching a Viral RNA Extraction Kit for Medium Throughput Processing of COVID-19 Samples for Detection Using RT-PCR

Dublin (ots/PRNewswire) - Magnostics is leading a consortium of University and National Researchers to develop and launch Viral RNA Extraction Kits for detection of COVID-19. A team of scientist from Saint Vincent University Hospital, National Virus Reference Laboratory, University College Dublin, and Magnostics ...

Hovione

Hovione Announces Partnership to Support Manufacturing of Antiviral Veklury® for COVID-19

Lisbon, Portugal (ots/PRNewswire) - Hovione today announced the signing of a partnership agreement with Ligand to significantly ramp up the production output of Captisol®. Captisol®, a Ligand product, is a chemically modified cyclodextrin proven to improve the solubility and stability of drugs. It is used in the formulation of Gilead's COVID-19 treatment Veklury® ...

Viroclinics Biosciences

Davide Molho, DVM Joins Viroclinics Biosciences as Chief Executive Officer

Rotterdam, Netherlands (ots/PRNewswire) - Viroclinics Biosciences B.V. ("Viroclinics") today announced the appointment of life sciences industry veteran Davide Molho, DVM as the company's new Chief Executive Officer. Dr. Molho succeeds Bob van Gemen, PhD who has served as the company's CEO since 2011. This transition is part of a planned succession strategy. Dr. ...

Schweizerischer Nationalfonds / Fonds national suisse

Meeting challenges through basic research

Bern (ots) - Many scientists are currently undertaking work on the Sars-CoV-2 virus. But hundreds of projects supported by the SNSF are already contributing to finding answers to the current health crisis. In Switzerland and around the world, the novel coronavirus has become a priority for scientific research. Projects supported by the Swiss National Science Foundation (SNSF) are no exception. A special call and a ...

IgNova GmbH

IgNova files patent application on antibody against COVID-19

Visbek, Germany (ots) - IgNova announced today that it has filed a patent application covering the use of passive immunization to control SARS-CoV-2 infection in humans. IgNova, a biopharmaceutical R&D start up, researches technology based on specific egg immunoglobulins (IgY). The patented IgY binds the spike protein of SARS-CoV-2, neutralizing the virus when it enters the mouth or nose and, therefore, inhibiting the ...

Zhejiang Hisun Pharmaceutical Co. Ltd

Hisun Pharmaceutical: Free of COVID-19, Governments Suggest Favipiravir

Taizhou, China (ots/PRNewswire) - Favipiravir is a broad-spectrum antiviral agent that inhibits the RNA-dependent RNA polymerase of RNA viruses. It has efficacy against a range of RNA viruses, including Ebola, influenza and COVID-19. No evident adverse reactions have been found since it came into the market. Unlike traditional antiviral drugs, Favipiravir can directly ...

Seqirus

First Adjuvanted Quadrivalent Influenza Vaccine by Seqirus Receives EU Approval

Maidenhead, England (ots/PRNewswire) - The European Commission has today given regulatory approval for the first adjuvanted quadrivalent influenza vaccine to become available across Europe. This new vaccine builds on the well-established technology used in an existing adjuvanted trivalent influenza vaccine (aTIV) available in several European countries. aTIV has ...

Neovii Pharmaceuticals AG

NEOVII Partners with Tel Aviv University to Develop Novel COVID-19 Vaccine

Rapperswil, Switzerland and Tel Aviv, Israel (ots/PRNewswire) - The epitope-based vaccine will target the most vulnerable part of the viral spike protein Ramot , Tel Aviv University's technology transfer company, and Neovii , a Swiss-based biopharmaceutical company and a member of Israel-based Neopharm Group, announced today that they have signed a research and license ...

Neovii Pharmaceuticals AG

NEOVII to Develop a Novel Vaccine for COVID-19 in an Exclusive Partnership With Tel Aviv University

Rapperswil, Switzerland (ots/PRNewswire) - Neovii, the Swiss-based biopharmaceutical company and a member of Israeli-based Neopharm Group, has signed a research and license agreement with Tel Aviv University's (TAU) RAMOT, its technology transfer company, to work in collaboration with a team led by Professor ...

Sophia Genetics

SOPHiA GENETICS and Paragon Genomics Join Forces Against the COVID-19 Coronavirus Pandemic

Lausanne, Switzerland, and Boston (ots/PRNewswire) - SOPHiA GENETICS, leader in Data-Driven Medicine, today announced that it is entering the fight against the COVID-19 coronavirus by extending its partnership with Paragon Genomics, who developed a next-generation sequencing (NGS) assay and leveraging the SOPHiA Platform analytical capabilities, as well as delivering ...

Merck Healthcare Germany GmbH

MAVENCLAD® (Cladribine Tablets) Approved As The First Short-Course Oral Treatment for Relapsing Remitting Multiple Sclerosis in Switzerland

Darmstadt, Germany (ots/PRNewswire) - - MAVENCLAD® is now approved in 52 countries worldwide - Approval brings forward new treatment option with a novel mechanism for highly active relapsing multiple sclerosis in Switzerland - Approval based on extensive clinical development program capturing more than 10,000 ...

Merck Healthcare Germany GmbH

MAVENCLAD® (Cladribine Tablets) Approved As The First Short-Course Oral Treatment for Relapsing Remitting Multiple Sclerosis in Switzerland

Darmstadt, Germany (ots/PRNewswire) - - MAVENCLAD® is now approved in 52 countries worldwide - Approval brings forward new treatment option with a novel mechanism for highly active relapsing multiple sclerosis in Switzerland - Approval based on extensive clinical development program capturing more than 10,000 ...

Schweizerischer Nationalfonds / Fonds national suisse

Latsis Prize 2018: Andrea Ablasser unlocks the secret of rapid virus defence